Skip to main content
OpenTrials
Completed

NCT Number: NCT05374447

Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy

The investigators will compare endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) with intranodal forceps biopsy (EBUS-IFB) as it relates to the rate of diagnosis of suspected sarcoidosis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The George Washington University Hospital

Washington D.C., District of Columbia, 20037, United States

About this study

This is prospective, single center randomized comparative study to determine the diagnostic yield and specimen quality of endobronchial ultrasound guided intranodal forceps biopsy of patients with suspected sarcoidosis based solely on imaging. This will be a single group study and will compare transbronchial needle aspiration via 19 or 21-gauge needle with intranodal forceps biopsy.

The study aims to answer a knowledge gap a as to whether the diagnostic yield and specimen quality of EBUS-TBNA with a 19G needle is less than those obtained by 1.9mm or greater intranodal forceps biopsy. The study proposed here will add to the field by further elucidating whether this procedure is beneficial for the diagnosis as it pertains to suspected sarcoidosis.

The anticipated required enrollment is 55 patients to achieve an α of 0.05 and β of 0.2. This assumes an unassisted diagnostic yield of 62.5% with standard of care EBUS-TBNA as reported in Ray et al, and a diagnostic supplementation to 80% yield with intranodal forceps biopsies.

References

  • Oki, M., Saka, H., & Sako, C. (2004). Bronchoscopic miniforceps biopsy for mediastinal nodes. Journal of Bronchology & Interventional Pulmonology, 11(3), 150-153.
  • Herth FJ, Morgan RK, Eberhardt R, Ernst A. Endobronchial ultrasound-guided miniforceps biopsy in the biopsy of subcarinal masses in patients with low likelihood of non-small cell lung cancer. Ann Thorac Surg. 2008 Jun; 85(6):1874-8.
  • Chrissian A, Misselhorn D, Chen A. Endobronchial-ultrasound guided miniforceps biopsy of mediastinal and hilar lesions. The Annals of Thoracic Surgery. 2011;92(1):284-288.
  • Franke KJ, Bruckner C, Szyrach M, Ruhle KH, Nilius G, Theegarten D. The contribution of endobronchial ultrasound-guided forceps biopsy in the diagnostic workup of unexplained mediastinal and hilar lymphadenopathy. Lung. 2012;190(2):227-232.
  • Herth FJF, Schuler H, Gompelmann D, et al. Endobronchial ultrasound-guided lymph node biopsy with transbronchial needle forceps: a pilot study. European Respiratory Journal. 2012;39(2):373-377.
  • Darwiche K, Freitag L, Nair A, et al. Evaluation of a novel endobronchial ultrasound-guided lymph node forceps in enlarged mediastinal lymph nodes. Respiration. 2013;86(3):229-236.
  • Ray AS, Li C, Murphy TE, et al. Improved diagnostic yield and specimen quality with endobronchial ultrasound-guided forceps biopsies: a retrospective analysis. The Annals of Thoracic Surgery. 2020;109(3):894-901

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Radiologic evidence of mediastinal and/or hilar lymphadenopathy
  • Attending radiologist or pulmonologist reports a possible diagnosis of sarcoidosis
  • Age 18 years or older

Exclusion criteria

*:

These are the characteristics that a participant must NOT have in order to be eligible to participate in the study.

Order Number Criteria

  • Severe pulmonary hypertension
  • Inability to undergo general anesthesia
  • Severe coagulopathy or bleeding diathesis
  • Previously diagnosed sarcoidosis
  • Patient presently taking clopidogrel
  • Patient deemed to be high risk for general anesthesia per anesthesiologist
  • Hemodynamic instability
  • Mediastinitis
  • Acute Hypercarbic Respiratory Failure (pCO2 >55mmHg)

Treatment and study plan

Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy

Procedure

Patients with mediastinal adenopathy will undergo EBUS-IFB and EBUS-TBNA during the same procedure to compare the yield of this procedure with EBUS-TBNA alone.

Other names: EBUS-IFB

Primary outcomes

  1. Diagnostic Yield

    Time frame: 1 year

    Diagnostic yield of EBUS-TBNA + EBUS-IFB compared to EBUS-TBNA alone

Secondary outcomes

  1. Duration of Procedure

    Time frame: 1 year

    Duration of combined EBUS-TBNA +IFB procedure compared to TBNA alone

  2. Complications

    Time frame: 1 year

    Complications of EBUS-TBNA +IFB procedure compared to TBNA alone

Sponsors and collaborators

Lead sponsor

George Washington University

Other

Registry information

Official study title

Evaluating the Diagnostic Yield and Specimen Quality With Endobronchial Ultrasound-Guided Intranodal Forceps Biopsies in Patients With Mediastinal and Hilar Lymphadenopathy: A Prospective Analysis

Important dates

Study start
2022
Primary completion
2025
Study completion
2026
First posted
May 16, 2022
Registry last updated
Apr 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.